

ALIMERA SCIENCES INC  
Form 8-K  
August 25, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 21, 2011**

**ALIMERA SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation)

**001-34703**

(Commission File Number)

**20-0028718**

(IRS Employer Identification No.)

**6120 Windward Parkway  
Suite 290**

**Alpharetta, Georgia**

(Address of Principal Executive Offices)

**30005**

(Zip Code)

Registrant's telephone number, including area code: **(678) 990-5740**

**Not Applicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On August 21, 2011, David S. Boyer, a practicing retina specialist at Retina-Vitreous Associates Medical Group in Los Angeles, California, presented new 36 month safety and efficacy results from the Alimera Sciences, Inc.'s Phase 3 FAME Study of ILUVIEN in patients with diabetic macular edema at the 29th Annual Meeting of the American Society of Retina Specialists. Dr. Boyer's presentation included new efficacy and safety data for patients receiving only one study treatment during the FAME Study. The slides presented by Dr. Boyer are filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---------------------|
| 99.1               | Presentation slides |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALIMERA SCIENCES, INC.

By: /s/ RICHARD S. EISWIRTH, JR.

Name: Richard S. Eiswirth, Jr.

Title: Chief Financial Officer and Chief Operating Officer

Dated: August 25, 2011